Cepheid PT Raised to $42.00 at Wedbush (CPHD)
Investment analysts at Wedbush hoisted their price target on shares of Cepheid (NASDAQ:CPHD) from $37.00 to $42.00 in a note issued to investors on Thursday, ARN reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 7.44% from the stock’s previous close.
Shares of Cepheid (NASDAQ:CPHD) traded up 0.59% during mid-day trading on Thursday, hitting $39.09. 313,820 shares of the company’s stock traded hands. Cepheid has a 52-week low of $28.12 and a 52-week high of $40.31. The stock’s 50-day moving average is $37.56 and its 200-day moving average is $36.60. The company’s market cap is $2.637 billion.
Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, July 18th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.02. The company had revenue of $96.00 million for the quarter, compared to the consensus estimate of $92.57 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue for the quarter was up 18.5% on a year-over-year basis. Analysts expect that Cepheid will post $-0.26 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Merrill Lynch downgraded shares of Cepheid (NASDAQ:CPHD) from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday. Separately, analysts at Bank of America Corp. downgraded shares of Cepheid (NASDAQ:CPHD) from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday. They now have a $41.00 price target on the stock, up previously from $39.00. They noted that the move was a valuation call. Finally, analysts at UBS AG reiterated a “buy” rating on shares of Cepheid (NASDAQ:CPHD) in a research note to investors on Thursday, September 5th. They now have a $40.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $40.53.
In other Cepheid news, Director Thomas Gutshall unloaded 3,000 shares of the stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $38.97, for a total value of $116,910.00. Following the transaction, the director now directly owns 90,175 shares in the company, valued at approximately $3,514,120. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.